Results and Discussion: Of the 246 patients in the intent-totreat
set, 89Æ4% completed the 3-day efficacy phase. PIDs
were 0Æ9 and 0Æ3 in the oxycodone/paracetamol and placebo
groups respectively, on day 1 (P < 0Æ001), and 1Æ5 and 0Æ3
respectively on day 3 (P < 0Æ001). Thirty-eight patients in the
treatment group, and 58 in the placebo group, suffered
breakthrough pain on day 3 (P < 0Æ001). The SF-6D score
decreased to 21Æ2±2Æ5 in the oxycodone/paracetamol group
at the end of the phase (P = 0Æ001). In the oxycodone/
paracetamol group, 67% rated GI as good, very good, or
excellent.